Skip to main content
Edward Soltesz, MD, Thoracic Surgery, Cleveland, OH

EdwardGSolteszMD

Thoracic Surgery Cleveland, OH

Adult Cardiac Surgery, Aortic Surgery, Cardiopulmonary Transplantation, Minimally Invasive Cardiac Surgery

Staff Cardiac Surgeon, Cleveland Clinic

Dr. Soltesz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Soltesz's full profile

Already have an account?

  • Office

    9500 Euclid Ave
    Cleveland, OH 44195
    Phone+1 800-223-2273

Education & Training

  • Brigham and Women's Hospital/Children's Hospital
    Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2005 - 2007
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Surgery, 1998 - 2005
  • Harvard Medical School
    Harvard Medical SchoolClass of 1998

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2006 - 2026
  • PA State Medical License
    PA State Medical License 2009 - 2016
  • MA State Medical License
    MA State Medical License 2001 - 2010
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Clinical Assessment and Collaboration Drive Sustained Improvement in Post-CABG Prolonged Ventilation Rates
    Clinical Assessment and Collaboration Drive Sustained Improvement in Post-CABG Prolonged Ventilation RatesNovember 29th, 2024
  • Auf Der STS-Jahrestagung Vorgestellte Umfangreiche Klinische Studie Zeigt Überlebensrate Von 79 % Bei Behandlung Mit Impella 5.5 Mit SmartAssist Herzpumpe
    Auf Der STS-Jahrestagung Vorgestellte Umfangreiche Klinische Studie Zeigt Überlebensrate Von 79 % Bei Behandlung Mit Impella 5.5 Mit SmartAssist HerzpumpeFebruary 1st, 2021
  • Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist
    Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssistJanuary 29th, 2021
  • Join now to see all

Grant Support

  • Gene Therapy For Chronic Heart FailureNational Heart, Lung, And Blood Institute2003

Professional Memberships